title: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
abstract: Research into actions of resveratrol, abundantly present in red grape skin, has been greatly stimulated by its reported beneficial health influence. Since it was recently proposed as a potential prostate cancer chemopreventive agent, we here performed an in vivo experiment to explore its effect in the Transgenic Rat for Adenocarcinoma of Prostate (TRAP) model, featuring the rat probasin promoter/SV 40 T antigen. Resveratrol suppressed prostate cancer growth and induction of apoptosis through androgen receptor (AR) down-regulation, without any sign of toxicity. Resveratrol not only downregulated androgen receptor (AR) expression but also suppressed the androgen responsive glandular kallikrein 11 (Gk11), known to be an ortholog of the human prostate specific antigen (PSA), at the mRNA level. The data provide a mechanistic basis for resveratrol chemopreventive efficacy against prostate cancer.
authors.affiliation: Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
authors.forename: Azman
authors.initials: A
authors.lastname: Seeni
authors.forename: Satoru
authors.initials: S
authors.lastname: Takahashi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Takeshita
authors.forename: Mingxi
authors.initials: M
authors.lastname: Tang
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sugiura
authors.forename: Shin-ya
authors.initials: SY
authors.lastname: Sato
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Shirai
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D059002:Androgen Receptor Antagonists; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001835:Body Weight / Q000187:drug effects; D019556:COS Cells; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D004958:Estradiol / Q000097:blood; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014176:Protein Biosynthesis; D012333:RNA, Messenger; D051381:Rats; D055647:Rats, Transgenic; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D000077185:Resveratrol; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012697:Serine Endopeptidases / Q000235:genetics / Q000378:metabolism; D013267:Stilbenes / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood; D025801:Ubiquitin / Q000378:metabolism
chemical_list: C410798:AR protein, human; D059002:Androgen Receptor Antagonists; D020533:Angiogenesis Inhibitors; D016588:Anticarcinogenic Agents; D012333:RNA, Messenger; D011944:Receptors, Androgen; D013267:Stilbenes; D025801:Ubiquitin; C114880:trypsin-like serine protease; D013739:Testosterone; D004958:Estradiol; D012697:Serine Endopeptidases; D000077185:Resveratrol